Stifel lowered the firm’s price target on Astrana Health (ASTH) to $56 from $70 and keeps a Buy rating on the shares ahead of Astrana reporting Q4 earnings on Thursday, February 27. The firm expects the call to be focused on integration of CHS and close of Prospect Health, 2025 guidance and medical cost trends, and progress in transitioning to full-risk, the analyst tells investors in a preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH: